New drug STRO-002 shows promise in early trial for advanced cancers
NCT ID NCT06238687
First seen Apr 16, 2026 · Last updated May 22, 2026 · Updated 3 times
Summary
This study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to other treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. While the drug may help control the disease, it is not a cure, and ongoing treatment or monitoring is likely needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM MALIGNANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Conditions
Explore the condition pages connected to this study.